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Background: Mucinous ovarian tumors represent a distinct histotype of epithelial ovarian cancer. The rarest
(2-4 % of ovarian carcinomas) of the five major histotypes, their genomic landscape remains poorly described. We
undertook hotspot sequencing of 50 genes commonly mutated in human cancer across 69 mucinous ovarian tumors.
Our goals were to establish the overall frequency of cancer-hotspot mutations across a large cohort, especially those
tumors previously thought to be “RAS-pathway alteration negative”, using highly-sensitive next-generation sequencing
as well as further explore a small number of cases with apparent heterogeneity in RAS-pathway activating alterations.
Methods: Using the Ion Torrent PGM platform, we performed next generation sequencing analysis using the v2
Cancer Hotspot Panel. Regions of disparate ERBB2-amplification status were sequenced independently for two
mucinous carcinoma (MC) cases, previously established as showing ERBB2 amplification/overexpression heterogeneity,
to assess the hypothesis of subclonal populations containing either KRAS mutation or ERBB2 amplification independently
or simultaneously.
Results: We detected mutations in KRAS, TP53, CDKN2A, PIK3CA, PTEN, BRAF, FGFR2, STK11, CTNNB1, SRC, SMAD4,
GNA11 and ERBB2. KRAS mutations remain the most frequently observed alteration among MC (64.9 %) and
mucinous borderline tumors (MBOT) (92.3 %). TP53 mutation occurred more frequently in carcinomas than
borderline tumors (56.8 % and 11.5 %, respectively), and combined IHC and mutation data suggest alterations
occur in approximately 68 % of MC and as many as 20 % of MBOT. Proven and potential RAS-pathway activating
changes were observed in all but one MC. Concurrent ERBB2 amplification and KRAS mutation were observed in
a substantial number of cases (7/63 total), as was co-occurrence of KRAS and BRAF mutations (one case). Microdissection
of ERBB2-amplified regions of tumors harboring KRAS mutation suggests these alterations are occurring in the same cell
populations, while consistency of KRAS allelic frequency in both ERBB2 amplified and non-amplified regions suggests this
mutation occurred in advance of the amplification event.
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Conclusions: Overall, the prevalence of RAS-alteration and striking co-occurrence of pathway “double-hits” supports a
critical role for tumor progression in this ovarian malignancy. Given the spectrum of RAS-activating mutations, it is clear
that targeting this pathway may be a viable therapeutic option for patients with recurrent or advanced stage mucinous
ovarian carcinoma, however caution should be exercised in selecting one or more personalized therapeutics given the
frequency of non-redundant RAS-activating alterations.
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Mucinous ovarian tumors are a rare histological type of
epithelial ovarian cancer (EOC), representing 2-4 % of
these malignancies [1–4]. Primary mucinous ovarian car-
cinomas are distinct from other EOC in both presentation
and outcome [3, 5–8]. Believed to develop along a con-
tinuum from benign cysts to borderline tumors to invasive
carcinomas, the majority of cases present as borderline
tumors (MBOT) or stage I mucinous carcinomas (MC).
Overall, prognosis is excellent, although in rare cases
where cancer has spread beyond the ovaries, outcomes
and response to conventional chemotherapy is poor.
In addition to sharing many biomarkers, MCs are
morphologically similar to adenocarcinomas of the pan-
creas and gastrointestinal tract, posing a challenge in dif-
ferentiating primary ovarian tumors from metastatic
disease [9–11]. Given the number of shared features be-
tween these disease entities, including a dominance of
RAS-activating changes, there is a potential for similar
therapeutic strategies and “umbrella” trials in women
with advanced stage or recurrent disease [12, 13].
Among mucinous tumors, the most prevalent mutations
occur in the mitogen activated protein kinase (MAPK) path-
way, including KRAS mutations and ERBB2 amplification/
overexpression [13]. Historically, KRASmutations have been
observed in greater than 75 % of mucinous ovarian tumors,
although differentiation of MBOT from MC and exclusion
of metastatic disease have not consistently been applied in
studies of this disease type [14–16]. Copy number analyses
have implicated loss of heterozygosity of chromosomal
regions 9p, 17p and 21q in the potential development
of these tumors [17]. Additional mutations have been
observed in BRAF, TP53, PTEN, PIK3CA and more re-
cently CDKN2A and RNF43 [14, 18–20]. However, rar-
ity of the disease has limited large-scale analyses of
mutational frequency among mucinous ovarian tumors
[19, 21]. Furthermore, apparent intratumoral heterogen-
eity among mucinous tumors represents an interesting
challenge for molecular profiling and potential personal-
ized therapeutic strategies [13, 22].
Our group recently reported on the most frequently
observed molecular alterations across mucinous tumors,
observing KRAS mutations in 43.6 % MCs and 78.8 %MBOTs and ERBB2 amplification/overexpression in 18.8 %
MCs and 6.2 % MBOTs, the latter being assessed by
immunohistochemistry, fluorescent- and chromogenic-in
situ hybridization (IHC, FISH & CISH) [13]. This analysis
suggested tumors lacking ERBB2 or KRAS abnormalities
tend to have poor prognosis, raising the question of
whether an alternative mutation may be contributing to
the pathology of this group [13]. In the current study, we
applied targeted deep sequencing to the same cohort from
our previous study [13], acquiring data for 37 MC and 26
MBOT. Two primary goals were sought: first, to search for
molecular alterations that may contribute to the pathogen-
esis of mucinous tumors without apparent RAS-activating
alterations and second, to investigate heterogeneity ob-
served in seemingly rare RAS-pathway “double-hit” cases
discovered in our previous study [13]. An outline of our se-
quencing strategy and resultant data is given in Fig. 1.
Methods
Sample cohort
Collection of specimens for experimental analysis was
performed by the OVCARE tumor bank and the Mayo
Clinic, use of material was approved by the UBC-BCCA
Research ethics board. All specimens underwent review
of pathology reports (authors CBG, JNM) as well as sin-
gle slide review of sampled material (author ANK and
MSA) to confirm diagnosis and establish cellularity.
Assessment of HPV infection was performed [23] to rule
out the possibility of rare metastasis from the cervix pre-
senting with mucinous histology in the ovary and all cases
were negative. DNA was extracted from formalin fixed
paraffin embedded (FFPE) tissue for sequencing analysis.
Where noted, microdissection of potentially distinct cell
populations was performed using ERBB2-IHC stained sec-
tions as a guide.
Ion torrent sequencing
Although we attempted to include the entire cohort de-
scribed in our previous study [13], we were limited by
availability and quality of material. DNA isolated from
FFPE tissue was available for 89 mucinous tumors, in-
cluding 30 MBOT and 59 MC. Following quality control
processing (described below), 37 MC and 26 MBOT
Cancer Hotspot Sequencing Strategy 
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Ion-Torrent Cancer Hotspot Sequencing (n=89) 
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Fig. 1 Outline of next-generation sequencing based sequencing strategy in the context of previously established cohort RAS-alterations defined
in Anglesio et al., 2013 [13]. Direct RAS-pathway alterations including suspected and known activating alteration to KRAS, BRAF, ERBB2, FGFR2,
and STK11 (the latter is presumed to alleviate negative signals on mTOR via TSC1/2 complex, similar to the effect of ERK1/2 activation)
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coded using the commercially available Cancer Hotspot
Panel v2 primer pool and IonXpress barcode adapter kit
as previously described [24, 25]. Libraries were quanti-
fied using Agilent High Sensitivity DNA chips, 20pM
barcoded libraries were pooled (4 samples at a time),
clonally amplified onto IonSphere particles using the Ion
OneTouch system, and loaded on Ion 316 chips for se-
quencing. Variant calling was performed using the Ion
Torrent Variant Caller with hg19 as a reference.Data processing and quality review
Successful sequencing was defined when there was at least
100x average depth of coverage for >80 % of amplicons
sequenced. Individual cases were manually reviewed to
evaluate overall sequencing quality (e.g., the number of
variant calls due to sequencing artifacts [26], percentage of
reads mapping to target region, etc.). Cases with poor
quality (n = 26) on manual review were excluded. We re-
port only on variants observed at >5 % allelic frequency
and >10x coverage, that correspond to non-synonymous
changes occurring in “hostspot” regions previously re-
ported to be somatic in COSMIC (Catalogue of somatic
mutations in cancer) [27], or are otherwise presumed to
be deleterious and somatic if the given point mutation or
insertion/deletion resulted in early termination.Immunohistochemistry
ERBB2 IHC (scored according to ASCO/CAP guidelines
[28]) was performed exactly as described in previously
[13]. An ERBB2 IHC score of 3+ was used as a proxy for
amplification status as this has been previously shown to
be highly concordant in these and other tumor types
(e.g. breast) [13, 29]. IHC for p53 was generated as de-
scribed previously [30] and scored on the same 3-tier
system: 0 = complete absence, 1 = up to 50 % nuclear
positivity and 2 = greater than 50 % nuclear positivity.
IHC for p53 was considered a proxy for mutations,
where both the null phenotype (0) and strongly positive
(2) were considered abnormal [30].
Results
Ion torrent sequencing
Quality sequencing data was obtained for 63 cases of pri-
mary ovarian mucinous tumors including 26 borderline
and 37 carcinomas (Fig. 1). Deleterious somatic mutations
were observed within 13 genes: KRAS, TP53, CDKN2A,
PIK3CA, PTEN, BRAF, FGFR2, STK11, CTNNB1, SRC,
SMAD4, GNA11, and ERBB2 (Table 1). Ion Torrent se-
quencing validated previously observed Sanger results
for KRAS mutations [13] and identified three additional
KRAS variants that were not detectable by Sanger (likely
due to low cellularity and restriction of the previous study
to the amino acid 12/13 hotspot region. (Figs. 2 & 3;
Table 1 Somatic hotspot mutation frequencies for MC and
MBOT
Carcinoma (n = 37) Mutation Events Frequency
KRAS 24 64.9
TP53 24 * 56.8
CDKN2A 8 * 18.9
PIK3CA 5 13.5
PTEN 2 * 2.7
BRAF 2 5.4
FGFR2 1 2.7
STK11 1 2.7
CTNNB1 2 5.4
SRC 1 2.7
SMAD4 1 2.7
Total Number Mutations 71
ERBB2 Amplification 14 § 37.8
Borderline Tumor (n = 26) Mutation Events Frequency
KRAS 24 92.3
TP53 3 11.5
CDKN2A 5 19.2
PIK3CA 4 15.4
PTEN 1 3.8
GNA11 1 3.8
ERBB2 1 3.8
Total Number Mutations 39
ERBB2 Amplification 3 § 11.5
Total # Mutations 110
*Multiple cases with 2 mutation events. Number of mutated cases were
used to establish frequency across cohort: TP53 (n = 21), CDKN2A (n = 7)
and PTEN (n = 1)
§Derived from Anglesio et al., 2013 [13]
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MBOT and two MC: MBOT: VOA491 - p.Gly12Val; MC:
OOU84 - p. Ala59Gly; and TMA3-41 - p.Gly12Val.
Mucinous borderline tumors
Among 26 MBOT cases, 39 presumed somatic mutations
were detected across seven genes: KRAS (24/26; 92.3 %),
TP53 (3/26; 11.5 %), CDKN2A (5/26; 19.2 %), PIK3CA (4/
26; 15.4 %), PTEN (1/26; 3.8 %), GNA11 (1/26; 3.8 %), and
ERBB2 (1/26; 3.8 %) (Table 1 & Fig. 2). Amongst these
MBOTs, KRAS mutations involved the “hotspot” for Gly-
12 only (Additional file 1). When grouped based on KRAS
hotspot mutant and ERBB2 amplification status we ob-
served 22 (84.6 %) KRAS+/ERBB2-, one (3.8 %) KRAS-/
ERBB2+, two (7.7 %) KRAS+/ERBB2+, and one (3.8 %)
KRAS-/ERBB2-; however, this last case harboured an
ERBB2 p.Asp769Asn mutation rather than amplification.
Despite the moderate frequency of amplification events,
activating mutations of ERBB2 have not previously beenimplicated in mucinous carcinoma pathogenesis. Muta-
tions to the 769 residue are expected to have an activating
effect given they are within the protein kinase domain
[31–33]. Such mutations have been reported previously in
both lung and esophageal cancers [34, 35].
Mucinous carcinoma
Within our cohort of 37 MC, we found 71 presumed som-
atic mutations within 11 different genes: KRAS (24/37;
64.9 %), TP53 (21/37; 56.8 %), CDKN2A (7/37; 18.9 %),
PIK3CA (5/37; 13.5 %), PTEN (1/37; 2.7 %), BRAF (2/
37; 5.4 %), FGFR2 (1/37; 2.7 %), STK11 (1/37; 2.7 %),
CTNNB1 (2/37; 5.4 %), SRC (1/37, 2.7 %), and SMAD4
(1/37; 2.7 %) (Table 1 & Fig. 3). Three cases had two
different, non-synonymous mutations in TP53 (OOU20,
VOA439, TMA1-6), one case had two mutations observed
in CDKN2A (OOU25), and one case had two PTEN muta-
tions (TMA1-16). With a single exception (OOU84 -
p.Ala59Gly), KRAS mutations involved the Gly-12 residue.
Co-occurrence of multiple mutations (including double
hits to the RAS-pathway) was observed at a higher fre-
quency within MC (26/37; 70.3 %) over MBOT (12/26,
46.2 %), however was not statistically significant (Fisher
exact test p = 0.0634).
Grouping of MC based on ERBB2 and KRAS status
resulted in 19 (51.4 %) KRAS+/ERBB2-, nine (24.3 %)
KRAS-/ERBB2+, five (13.5 %) KRAS+/ERBB2+, one (2.7 %)
KRAS-/ERBB2-, and three KRAS- cases undefined ERBB2
amplification status (Fig. 3). Among the three KRAS-/
ERBB2 undefined cases, alternative RAS-pathway acti-
vating mutations were observed in two cases (TMA1-2:
FGFR2 p.Ser252Trp; TMA3-12: BRAF p.Val600Glu),
and the third (TMA2-39) having an STK11 inactivating
change that may result in alleviation of negative signals
on mTOR via TSC1/2 complex, similar to the effect of
ERK1/2 activation [36, 37]. Ultimately, one case (TMA1-1)
is definitively negative with respect to RAS-alteration sta-
tus given the current screen.
TP53 status amongst mucinous tumors
Immunohistochemical scoring of p53 expression was
generally concordant with mutation status (Figs. 2 & 3).
A TMA-based evaluation of p53 protein was done for
the full cohort of Mayo and Vancouver samples, with in-
terpretable results obtained for 15/26 MBOT and 29/37
MC where sequencing was also available. Of these, three
MBOT cases had abnormal staining patterns for p53,
and occurred in KRAS mutant or ERBB2 amplified cases.
TMA1-23 and TMA3-49 showed complete loss of p53
staining; however, no mutation was observed in the re-
gions sequenced, which may be the result of larger dele-
tions or mutation outside of the hotspot panel. Twelve
MC cases had abnormal p53 staining and appeared to be
well distributed across all four groups of KRAS mutant
Fig. 2 Mutation frequencies and immunohistochemistry scores for 26 mucinous borderline tumors. Solid color in any of the first 13 columns
represents a presumed somatic (COSMIC) hotspot mutation in the given case. In the last three columns numbers represent binarized IHC score for p53
and § “Original ERBB2 amplification and KRAS mutation” status derived from Anglesio et al., 2013 [13] where 0 = Negative, 1 = Positive, X = Unknown,
the latter derived from IHC, FISH, and/or CISH. IHC for p53 is displayed as three-tiered IHC score where 0 (no staining) and 2 (>50 % positive nuclei)
represent abnormal p53 status and 1 (1-50 % positive nuclei) represents normal p53 status (x = data unavailable)
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OOU25, TMA1-36 and TMA1-1) had p53 staining
abnormalities that occurred without detectable muta-
tion. Finally, seven MC (18.9 %; TMA1-46, OOU 20,
OOU 82, TMA2-16, TMA1-44, VOA 321 and VOA 695)
were found to have presumed-somatic TP53 mutations,
but did not have corresponding IHC abnormalities. It
should be noted that the Ion-Torrent panel does not se-
quence the entirety of TP53 and is not well suited for
the detection of exon-level (or larger) deletions, which
may result in a null-phenotype by IHC. Further, our ana-
lysis may be partially confounded by non-somatic vari-
ants, whether contaminating the COSMIC database
(“false-positive”, non-somatic in our context), or having
subtle effects on protein stability/unknown functional
effects: i.e. the presence of a “presumed somatic muta-
tion” may not yield a mutant overexpression or null-
phenotype. Overall, TP53 mutations were more preva-
lent in MC, and no enrichment of TP53 was associated
with any RAS-pathway mutation groups. Using p53 IHC
data alone (Additional file 2) and expanding to all avail-
able cases, we observed no difference in overall or
progression-free survival for the MC cohort (Additional
file 3). Corresponding survival analysis for borderline tu-
mors was uninformative due to cohort sample size andcensoring. Our data set also failed to show enrichment
of TP53 mutation, in either borderline or carcinomas.
RAS-pathway heterogeneity
Two cases of MC (VOA695 and VOA439) were previously
described to be heterogeneous for ERBB2 amplification/
overexpression [13]. As greater access was available for
these local cases, a full series of clinical blocks was ex-
amined for ERBB2 3+ and negative IHC. Positive and
negative regions were then fine-needle microdissected
with both front and back ERBB2-stained sections as a
guide to ensure consistency in IHC positive (3+) and
negative (0) regions. Sequencing of the disparate regions
of VOA439 confirmed the previously observed KRAS
p.Gly12Asp mutation at similar allelic frequency in both
ERBB2+ and ERBB2- regions: 46.1 % and 43.5 % respect-
ively (Fig. 4). Two TP53 and one CDKN2A mutations
were also found in both regions at similar allelic frequen-
cies. Similar results were observed in case VOA695 across
ERBB2+ and ERBB2- regions: KRAS p.Gly12Asp mutation
at 18.1 % and 16.6 %, and TP53 p. Ser127Pro mutation at
10.5 % and 19.6 % allelic frequency, respectively. Double-
hit RAS-pathway alterations were confirmed in six add-
itional MC cases (total 21.6 %). Double-hits were observed
in both MBOT (two cases; 7.7 %) and MC, but were more
Fig. 3 Mutation frequencies and immunohistochemistry scores for 37 mucinous carcinoma. As in Fig. 2, Solid color in any of the first 13 columns
represents a presumed somatic (COSMIC) hotspot mutation in the given case. In the last three columns numbers represent binarized IHC score for p53
and § “Original ERBB2 amplification and KRAS mutation” status derived from Anglesio et al., 2013 [13] where 0 = Negative, 1 = Positive, X = Unknown,
the latter derived from IHC, FISH, and/or CISH. IHC for p53 is displayed as three-tiered IHC score where 0 (no staining) and 2 (>50 % positive nuclei)
represent abnormal p53 status and 1 (1-50 % positive nuclei) represents normal p53 status
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of RAS-pathway alterations in comparison to cellularity
estimates suggested that RAS-pathway mutations may be
more likely to be hemizygous or homozygous (Additional
file 1) although copy number analysis was not available to
validate this.
Discussion
In the current study we provide quantitative interroga-
tion of MC and MBOTs using amplicon-based hotspot
sequencing. Our re-sequencing efforts confirmed KRAS
mutations to be the most frequent molecular alteration
amongst mucinous tumors, appearing more common in
borderline malignancies over carcinomas (92.3 % versus
64.9 %, respectively; Fisher exact p = 0.0157). These
values reflect what was previously reported [13]; how-
ever, improved sensitivity through the use of next gener-
ation sequencing identified KRAS mutations in three
cases previously believed to be wild type (one MBOT
and two MC). We further added to the complement of
known RAS-activating mutations in observing mutations
in BRAF (two MC), as well as previously unreportedpotentially RAS-activating alterations in FGFR2, ERBB2,
and STK11, each affecting a single carcinoma. As noted
above, inactivating mutation of STK11 could be consid-
ered an alternative mechanism to RAS-activation outside
of typical KRAS/BRAF mutations [36, 37], an important
point given the occurrence of this mutation in one of
only two MC without other known RAS alterations.
Most other mutations observed here have previously
been implicated in the biology of mucinous ovarian tu-
mors (KRAS, BRAF, TP53, CDKN2A, PIK3CA, PTEN)
[14, 15, 18–20, 38]. Reported mutation frequencies vary,
with small sample size and inconsistent diagnostic cri-
teria likely at the heart of the variance observed in the
literature. To the best of our knowledge, mutations
within FGFR2, ERBB2 (missense/activating), STK11,
GNA11, SRC, CTNNB1, and SMAD4 have not been pre-
viously reported in mucinous ovarian tumors. GNA11
mutations, such as the one observed in an MBOT have
been shown to up-regulate RAS-pathway activation [39],
and while SRC mutations have not been previously re-
ported in ovarian MC, others have suggested a high level
of SRC protein kinase activity in these tumors [40, 41].
ERBB2+ ERBB2- 
Case Gene Mutation 
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Coverage 
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KRAS p.G12D 
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4208 1939 46.1 
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9731 4230 43.5 2.6 COSM521 
TP53 p.Y205* 1040 498 47.9 2443 1631 66.8 18.9 COSM43928 
TP53 p.L194V 1009 467 46.3 2431 1623 66.8 20.5 COSM46117 
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Fig. 4 ERBB2 immunohistochemical heterogeneity in two MC and sequencing results from each distinct component. ERBB2+ regions were
microdissected and sequenced independently from the ERBB2- components to compare mutation events. Identical KRAS mutations were
observed in the ERBB2+ and ERBB2- regions for both cases. ERBB2 high-intensity staining regions was used as a proxy for gene amplification
status, as regions previously defined by this high-level IHC staining correlated perfectly with FISH and/or CISH data suggesting amplification
of the ERBB2 gene [13]
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identifiable RAS-pathway alteration, all but eradicating
the RAS-activation negative group. Although relatively
broad, our screen was not genome-wide and it is fore-
seeable that other rare RAS-activating alterations could
be uncovered. This re-analysis also implies there is little
difference in survival in tumors lacking RAS-pathway
alterations, if any of these so-called “RAS-negative”
tumors exist. We were also unable to show survival dif-
ference between ERBB2-positive, KRAS-positive, or non-
KRAS/ERBB2-altered cases. However, it should be noted
that our total cohort numbers have depleted since our
previous analysis, and with additional RAS-pathway al-
terations defining unique groups, the number of samples
per group were insufficient for meaningful conclusions
on outcome.
Intratumoral heterogeneity among mucinous ovarian
tumors, which previously seemed to be restricted to het-
erogeneity in ERBB2 status (observable in situ using
FISH, CISH or IHC), presents a challenge for standard
molecular analyses [13]. Based on our previous data
suggesting a near-mutual exclusivity of RAS-pathway
alterations in MC as well as numerous similar examplesin the literature [42–44], we expected KRAS mutations
would be restricted to regions lacking ERBB2 positivity.
Surprisingly, KRAS mutations were found at near-identical
frequencies in both ERBB2+ and ERBB2- regions of both
examined MC. In fact, multiple alterations to the RAS-
pathway were observed within two MBOT and six MC.
This suggests that the KRAS mutations in both of these
cases represent an ancestral alteration, present prior to the
amplification of ERBB2. Further, this supports a model
wherein RAS-pathway alterations are unlikely to be func-
tionally equivalent.
Alterations involving the TP53 locus occurred more fre-
quently in MC than MBOT (21/37; 56.8 % and 3/26; 11.5 %,
respectively). Aberrant expression of p53, assessed by
IHC (scores of 0 and 2), suggest underlying genetic alter-
ations in cases where no mutation were observed, a dis-
tinct possibility given the limits of our screening strategy.
Considering both IHC and sequencing data, we estimate
the frequency of TP53 alterations to be slightly higher
than indicated in the mutation data alone and we estimate
rates of approximately 20 % and 68 % for MBOT and
MC, respectively. Unfortunately, we were unable to show
an effect for p53 mutation (based on IHC status or
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or MC (Additional file 3). It may be reasonable to suggest
acquisition of TP53 mutation imparts genomic instability
that in turn leads to accumulation of other mutations
permissive overcoming senescence and other anti-growth
signals induced by constitutive RAS-activation (for ex-
ample through acquisition of PTEN loss of function muta-
tions seen here). Should a suitable cohort be identified, a
future study may be able to evaluate accumulated DNA
copy number changes and clonal composition between
MBOT and MUC. This may suggest a correlation between
genomic complexity and acquisition of p53 mutations
and/or secondary RAS-activating mutations, however this
is conjecture at this point.
Conclusions
Previous data on mucinous ovarian cancers suggested a
less favorable prognosis for cases not carrying a known
RAS-pathway alteration [13], similar to reports in the ovar-
ian low-grade serous/serous borderline tumor spectrum
[45]. However, this finding is not reproducible in our
current study where greater sensitivity in detection is ap-
plied and additional RAS-pathway alterations are consid-
ered. In general, we saw an increased frequency of multiple
RAS-pathway alterations and TP53 mutations amongst
carcinomas versus borderline tumors in our cohort, sug-
gesting mutations in both of these pathways are critical in
accelerating the progression of mucinous ovarian tumors.
Save for a single case of MC, RAS-pathway activation is
ubiquitious among mucinous ovarian tumors, in fact even
this final case may have a cryptic RAS-activating alteration
unseen by our hotspot screening strategy. Of particular
importance, so-called “double hits” to this pathway were
shown to overlap the same populations of cells in two
cases where testing for this overlap was possible. This
finding suggests different RAS mutations contribute, at
least in part, unique functionality with respect to mu-
cinous tumor progression.
Finally, the overall patterns of mutations amongst these
tumors are not dissimilar to other mucinous tumor types,
including pancreatic and appendiceal tumors [46–49]. Al-
though extensive care was taken to exclude metastatic dis-
ease, limited certainty of primary ovarian tumor versus
metastatic disease holds true for virtually all studies on
MC and MBOT, and remains a concern here. However, an
overlapping relationship, either with respect to the origins
or mechanisms mediating transformation, between ovar-
ian mucinous and other peritoneal mucinous tumors is
not unrealistic. Commonalities between these mucinous
cancers may help explain the inherent chemoresistance in
contrast to other EOC’s and suggest so-called umbrella
trial designs, grouping together cancers with similar mo-
lecular presentation, may provide a realistic option for
treatment development in this relatively rare tumor type.Additional files
Additional file 1: Hotspot sequencing, cellularity estimates and
HPV infection status data for 26 mucinous borderline tumors and
37 mucinous carcinomas.
Additional file 2: p53 immunohistochemistry results and outcome
data for entire cohort of MBOT and MC.
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